Skip Navigation



NDT Plus Advance Access published online on November 5, 2009
NDT Plus, doi:10.1093/ndtplus/sfp158
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Katsanos, K. H.
Right arrow Articles by Tsianos, E. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press [on behalf of ERA-EDTA]. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Reversible proteinuria after adalimumab discontinuation in a patient with Crohn's disease

Konstantinos H. Katsanos, Dionysios Theiakos, Ioannis Vagias, Dimitrios Christodoulou and Epameinondas V. Tsianos

1st Department of Internal Medicine & Hepato-Gastroenterology Unit University Hospital of Ioannina Ioannina, Greece E-mail: etsianos@uoi.gr

The first 10% of the full text of this article appears below.

Sir,

Renal complications are not infrequent in patients with inflammatory bowel diseases and seem to be more prevalent in patients with Crohn's disease. The spectrum of renal complications in Crohn's disease patients involves nephrolithiasis, amyloidosis, renal hypertension, glomerulonephritis (from minimal change nephropathy to rapidly progressive crescentic), tubulointerstitial abnormalities and iatrogenic complications related to medications such as aminosalicylates and . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?